162 related articles for article (PubMed ID: 33564402)
1. Tyrosine kinase inhibitor-induced hypertension-marker of anti-tumour treatment efficacy or cardiovascular risk factor?
Ptinopoulou AG; Sprangers B
Clin Kidney J; 2021 Jan; 14(1):14-17. PubMed ID: 33564402
[TBL] [Abstract][Full Text] [Related]
2. Changes in blood pressure during treatment with the tyrosine kinase inhibitor lenvatinib.
Saito K; Fujii H; Kono K; Hirabayashi K; Yamatani S; Watanabe K; Goto S; Komatsu S; Fukumoto T; Nishi S
Clin Kidney J; 2021 Jan; 14(1):325-331. PubMed ID: 33564435
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma.
Lee N; Lee JL; Lee JY
Target Oncol; 2023 Mar; 18(2):247-255. PubMed ID: 36826462
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine Kinase Inhibitor-Induced Hypertension.
Agarwal M; Thareja N; Benjamin M; Akhondi A; Mitchell GD
Curr Oncol Rep; 2018 Jun; 20(8):65. PubMed ID: 29931399
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment.
Budolfsen C; Faber J; Grimm D; Krüger M; Bauer J; Wehland M; Infanger M; Magnusson NE
Curr Vasc Pharmacol; 2019; 17(6):618-634. PubMed ID: 30706818
[TBL] [Abstract][Full Text] [Related]
6. Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor.
Waliany S; Sainani KL; Park LS; Zhang CA; Srinivas S; Witteles RM
JACC CardioOncol; 2019 Sep; 1(1):24-36. PubMed ID: 34396159
[TBL] [Abstract][Full Text] [Related]
7. Axitinib Induces and Aggravates Hypertension Regardless of Prior Treatment With Tyrosine Kinase Inhibitors.
Kadowaki H; Ishida J; Akazawa H; Yagi H; Saga-Kamo A; Umei M; Matsuoka R; Liu Q; Matsunaga H; Maki H; Sato Y; Kume H; Komuro I
Circ Rep; 2021 Mar; 3(4):234-240. PubMed ID: 33842729
[No Abstract] [Full Text] [Related]
8. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.
Nadal R; Amin A; Geynisman DM; Voss MH; Weinstock M; Doyle J; Zhang Z; Viudez A; Plimack ER; McDermott DF; Motzer R; Rini B; Hammers HJ
Ann Oncol; 2016 Jul; 27(7):1304-11. PubMed ID: 27059553
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of anti-PD-1 monotherapy
Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
[TBL] [Abstract][Full Text] [Related]
10. Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report.
Furuto Y; Hashimoto H; Namikawa A; Outi H; Takahashi H; Horiuti H; Honda K; Shibuya Y
BMC Nephrol; 2018 Oct; 19(1):273. PubMed ID: 30340546
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular adverse events in patients with hepatocellular carcinoma receiving vascular endothelial growth factor inhibitors.
Yuan F; Lenneman C; Krone R; Williams GR; Outlaw D; Katsnelson M; Lirette S
Pharmacotherapy; 2024 Mar; 44(3):214-223. PubMed ID: 38009283
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
[TBL] [Abstract][Full Text] [Related]
13. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: Potential role of vascular endothelial dysfunction.
Sueta D; Suyama K; Sueta A; Tabata N; Yamashita T; Tomiguchi M; Takeshita T; Yamamoto-Ibusuki M; Yamamoto E; Izumiya Y; Kaikita K; Yamamoto Y; Hokimoto S; Iwase H; Tsujita K
Atherosclerosis; 2017 May; 260():116-120. PubMed ID: 28390289
[TBL] [Abstract][Full Text] [Related]
15. Association between baseline blood pressure and the incidence of lenvatinib-induced hypertension in patients with thyroid cancer.
Shibutani Y; Tajiri K; Suzuki S; Enokida T; Sagara A; Okano S; Fujisawa T; Sato F; Yumoto T; Sano M; Kawasaki T; Tahara M
Cancer Med; 2023 Nov; 12(22):20773-20782. PubMed ID: 37902136
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular toxicities following the use of tyrosine kinase inhibitors in hepatocellular cancer patients: a retrospective, pharmacovigilance study.
Lai X; Wan Q; Jiao SF; Sun XC; Hu JF; Peng HW
Expert Opin Drug Saf; 2024 Mar; 23(3):287-296. PubMed ID: 37608525
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
18. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Miyake H; Imai S; Harada K; Fujisawa M
Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
[TBL] [Abstract][Full Text] [Related]
19. Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients.
Izumi K; Itai S; Takahashi Y; Maolake A; Namiki M
Oncol Lett; 2014 Jul; 8(1):305-308. PubMed ID: 24959266
[TBL] [Abstract][Full Text] [Related]
20. Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma.
Rimassa L; Danesi R; Pressiani T; Merle P
Cancer Treat Rev; 2019 Jul; 77():20-28. PubMed ID: 31195212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
